A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872 on ClinicalTrials.gov · last registry update 2026-10-01

An unusually large phase 2: 330 participants, more than double the 110 typical for the stage. Due to report 5 February 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Hoffmann-La Roche
Sponsor type: Industry
Enrollment: 330
Started: 2025-08-19
Primary completion: 2028-02-05 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-01	Reporting date moved	2026-11-27 → 2028-02-05 15 months later
2026-10-01	Enrollment changed	240 → 330 (+90) participants

Primary outcome

RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.